Ecolab, Repligen launch DurA Cycle for large-scale biologic manufacturing

Ecolab has announced the commercial launch of Purolite's DurA Cycle, a new protein A chromatography resin designed for large-scale purification processes. This product, developed in collaboration with Repligen Corporation, will be introduced at the BIO International Convention (BIO 2024), taking place June 3–6 in San Diego. This launch is a significant step in the strategic partnership between Purolite and Repligen, underscoring Ecolab's commitment to innovation in the bioprocessing industry.

DurA Cycle is intended for the commercial manufacturing of monoclonal antibodies, a process where cost efficiency is crucial for biologic drug developers. It is the latest addition to Purolite's range of resins, following the introduction of two others in the past eighteen months, aimed at addressing the purification challenges of increasingly complex drugs.

"The launch of DurA Cycle chromatography resin highlights Ecolab’s century-long tradition of innovation and continuous investment in Purolite,” said Srini Paluri, senior vice president and general manager at Purolite, in the press release. “This new resin helps biologic developers enhance manufacturing efficiencies, lower costs, and speed up the delivery of new treatments to the clinic."

"The bioprocessing industry requires partnerships that can tackle the most complex challenges in biologic manufacturing. Our work with Purolite, an Ecolab Company, drives industry progress by providing advanced solutions that meet these needs,” explained Ralf Kuriyel, vice president of research & development at Repligen, highlighting the importance of their collaboration. “Together, we are shaping the future of bioprocessing."

The announcement of DurA Cycle follows Purolite’s recent investment in a new bioprocessing production facility in Landenberg, Pennsylvania, complementing its existing United Kingdom-based facility and enhancing its manufacturing capabilities to meet growing customer demand.